drugset
drugset / Trial / NCT05854511

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

NCT05854511 ↗

Phase 3 Unknown 30 enrolled Ain Shams University Cairo University · collab
NaSingle-groupOpen-labelTreatment

Summary

This is an interventional, single center, single arm clinical trial to assess the pharmacokinetics, safety, efficacy, and acceptability of daclatasvir plus sofosbuvir in treatment-naïve children weighing between 14 and 35 kg with chronic HCV GT 1-6 infection.

Timeline

Start
2022-06-05
Primary completion
2023-12-31
Completion
2024-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Daclatasvir Small molecule 30 mg Oral
Subject Sofosbuvir Small molecule 200 mg Oral

Indications

chronic hepatitis C virus infection